Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EN3348 (MCC) vs mitomycin C in BCG recurrent or refractory non–muscle invasive bladder cancer
2011-003496-11Phase 3Terminated
- Sponsor
- Endo International plc
- Start
- Nov 2011
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of mycobacterial cell wall-DNA complex in non-muscle-invasive bladder cancer (NMIBC) (2 arms), sponsored by Endo International plc. Primary endpoint: Event-free survival. Started Nov 2011; status: terminated.
02
Drugs
mycobacterial cell wall-DNA complex
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on 2011-003496-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003496-11.